Search | Clinical Trials Finder

Conditions: Rheumatoid Arthritis (RA)
Interventions: TNF Antagonist (enbrel, humire, remicade, cimzia, symponi), Abatacept, Tocilizumab; Drug
Lead sponsor: Dr. Larry W. Moreland; Other
Eligibility: 18 Years to 64 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 402 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 29
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Washington D.C., District of Columbia + 26 more

Conditions: Dementia, Alzheimer Disease
Interventions: Methotrexate, Anti-TNF; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 34,647 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Anal Squamous Intraepithelial Lesion (ASIL), HPV DNA
Interventions: Anal Pap smear and HPV DNA testing; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 310 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol; Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 19
States / cities: Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more

Conditions: Rheumatoid Arthritis
Interventions: 89Zr-DFO-CZP; Drug
Lead sponsor: Robert Flavell, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Certolizumab pegol; Other · Biological
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 41
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 38 more

Conditions: Rheumatic Disease
Interventions: Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib; Drug · Biological
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Psoriasis, Plaque Psoriasis
Interventions: Certolizumab Pegol, Etanercept, Placebo; Biological · Other
Lead sponsor: UCB Biopharma S.P.R.L.; Industry
Eligibility: 18 Years and older
Enrollment: 559 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 19
States / cities: Mobile, Alabama • Little Rock, Arkansas • Beverly Hills, California + 16 more

Conditions: Rheumatoid Arthritis
Interventions: Tofacitinib, TNF Inhibitor; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 105,711 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol (CDP870); Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 950 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • La Jolla, California + 23 more

Conditions: Crohn's Disease
Interventions: certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 7
States / cities: Orange, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Conditions: Herpes Zoster, Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
Interventions: Not listed
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 35 Years to 49 Years
Enrollment: 97 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Rheumatoid Arthritis
Interventions: Cimzia, Magnetic Resonance Imaging (MRI), High-resolution peripheral quantitative computed tomography (HR-pQCT); Drug · Device
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol, Placebo, Methotrexate; Biological · Other
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 70
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 63 more

Conditions: Crohn's Disease
Interventions: certolizumab pegol; Drug
Lead sponsor: Shafran Gastroenterology Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Winter Park, Florida

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab Pegol (CZP), Adalimumab (ADA), Methotrexate (MTX); Biological · Drug
Lead sponsor: UCB Pharma SA; Industry
Eligibility: 18 Years and older
Enrollment: 915 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 62
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Tucson, Arizona + 56 more

Conditions: Crohn's Disease
Interventions: Certolizumab pegol, Azathioprine; Biological · Drug
Lead sponsor: Gastroenterology Research of America; Other
Eligibility: 18 Years to 70 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Rheumatoid Arthritis
Interventions: TNF inhibitors, DMARDs; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 149 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol; Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 36
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 33 more

Conditions: Rheumatoid Arthritis
Interventions: Certolizumab pegol (CZP), Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 1,648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 101
States / cities: Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more

Conditions: Arthritis, Psoriatic
Interventions: CZP 200 mg Q2W, CZP 400 mg Q4W, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 409 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 27
States / cities: Birmingham, Alabama • Tuscaloosa, Alabama • Peoria, Arizona + 24 more

Conditions: Axial Spondyloarthrithis, Ankylosing Spondylitis
Interventions: Certolizumab Pegol, Placebo; Biological · Other
Lead sponsor: UCB BIOSCIENCES GmbH; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 736 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 16
States / cities: Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 13 more

Conditions: Crohn's Disease
Interventions: certolizumab pegol; Biological
Lead sponsor: Atlanta Gastroenterology Associates; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy

Anal Dysplasia in Patients With Inflammatory Bowel Disease and Healthy Controls

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

Zr-89 Cimzia PET Imaging Rheumatoid Arthritis

Assessing the Use of Certolizumab Pegol in Adult Subjects With Rheumatoid Arthritis on the Antibody Response When Receiving Influenza Virus and Pneumococcal Vaccines

Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty

Efficacy and Safety Study of Certolizumab Pegol (CZP) Versus Active Comparator and Placebo in Subjects With Plaque Psoriasis (PSO)

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

A Placebo Controlled Study to Assess Efficacy and Safety of Certolizumab Pegol in the Treatment of Rheumatoid Arthritis

Extension Study to Assess Long Term Safety in Children and Adolescents With Crohn's Disease Receiving Certolizumab Pegol

Identifying Young Inflammatory Bowel Disease Patients at Risk for Herpes Zoster

Novel Imaging Markers for Rheumatoid Arthritis

A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis

Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease

RHYTHM (Formerly Escape II Myocardium)

Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis

Study to Evaluate Maintenance of Sustained Remission of axSpA With CZP Compared to Placebo

Optimizing Cimzia in Crohn's Patients